ClinicalTrials.gg
CompletedNCT03860038Updated Apr 24, 2025

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of TJ202 and Dexamethasone in Multiple Myeloma in Relapse and Refractory Multiple Myeloma, sponsored by TJ Biopharma Co., Ltd.. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by TJ Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
68th of 373
113 · median 45
Started
2019
with 20 others
Phase 2
217 of 381
18 open now
Registered
270th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 68th largest by enrollment of the 373 interventional ones that give a count, is one of 21 that started in 2019, is one of 217 in phase 2, and was the 270th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of treatment.

Read the detailed description

A total of 82 subjects with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of treatment will be enrolled in this study. Prior lines of treatment must include a proteasome inhibitor (PI) and an immunomodulator (IMiD). All subjects will receive TJ202 and dexamethasone (DEX) in the study. The treatment will continue until endpoint events such as intolerance or progressive disease (PD).

03

Conditions studied

  • Multiple Myeloma in Relapse
  • Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18, male or female;
  2. Subject must have had documented MM;
  3. At screening phase, subject must have ;
  4. Subject is in a state of progressive disease (PD);
  5. Subject must have of no less than 6 months;
  6. Subject must have an (Eastern Cooperative Oncology Group) performance status score of 0\~2;

Exclusion criteria

Exclusion criteria:

  1. Subject has received anti-CD38 monoclonal antibody treatment previously;
  2. Subject has received CAR-T cell therapy previously;
  3. Subject has previously received allogenic stem cell transplant, or subject has received stem cell transplant within 3 months before administration of the study agent;
  4. Primary multiple myeloma (subject failed to generate any minimal response or any degree of response to any therapy);
  5. Subject has received anti-myeloma treatment (radiotherapy is excluded) within 4 weeks or 5 PK half-lives of the treatment, whichever longer, before the first study agent administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    TJ202

    Drug: TJ202 and Dexamethasone

Interventions

  • DrugTJ202 and Dexamethasone

    Drug pages: Felzartamab · Dexamethasone

    one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    defined as the proportion of subjects achieving stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

Secondary outcomes

  1. Clinical benefit rate (CBR)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

  2. Duration of response (DOR)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

  3. Time to progression (TTP)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

  4. Time to response (TTR)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

  5. Progression-free survival (PFS)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

  6. Overall survival (OS)

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

Other outcomes

  1. minimal residual disease (MRD) assessment

    For subjects reaching CR and above, their bone marrow samples will be collected for exploratory minimal residual disease (MRD) assessment at the central laboratory.

    Time frame: end of study [ Time Frame: Approximately up to 2 years ]

07

Study locations

18 sites
  • Beijing Chao-Yang Hospital,Capital medical university
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Nanfang Hospital of SMU
    Guangzhou, Guandong, China
  • The second people's Hospital of Shenzhen
    Shenzhen, Guangdong, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangzhou, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • The first Bethune hospital of Jilin University
    Changchun, Jilin, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai, China
  • National Taiwan University Hospital
    Taiwan, Taiwan, China
  • Tri-Service General Hospital
    Taiwan, Taiwan, China
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • Sir Run Run Shaw Hospital,affiliated with the Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital, College of Medicine,Zhejiang University
    Hangzhou, Zhejiang, China
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jan 2023, 48 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 48 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Mar 1, 2019
StartActual
Jan 28, 2019
Primary completionActual
Jan 28, 2023
CompletionActual
Jan 28, 2023
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03860038
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
Jan 28, 2019
Primary completion
Jan 28, 2023
Completion
Jan 28, 2023
Last update
Apr 24, 2025

Study contacts

Lugui Qiu, Doctor
principal investigator · Institute of Hematology & Hospital of Blood Diseases CAMS&PUMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Felzartamab · Dexamethasone

Start the discussion